


# ANMC Clostridium difficile Infection (CDI) Treatment Guideline

Signs & Symptoms	Laboratory Findings
<ul style="list-style-type: none"> <li>Abdominal cramping/discomfort</li> <li>≥3 watery/unformed stools in a 24 hour period</li> <li>Mucous and/or blood in stool</li> </ul>	<ul style="list-style-type: none"> <li>Positive <i>Clostridium difficile</i> DNA amplification test (2 hour turnaround for results)</li> <li>Test of cure should not be performed.</li> <li>Children &lt;2 years old should not be routinely tested for C.diff when presenting with diarrhea due to high carriage rates and high risk of false positive results</li> </ul>

## Risk Factors

Host	Disruption in flora
<ul style="list-style-type: none"> <li>Recent hospitalization or known contact in the community</li> <li>Immunocompromised</li> <li>Female gender</li> <li>Age &gt; 65 yo</li> </ul>	<ul style="list-style-type: none"> <li>Antibiotics in previous 90 days</li> <li>PPI/H2 Blocker use (risk of causing <i>C.difficile</i>: PPI&gt;H2 Blocker&gt;Antacids)</li> <li>Antineoplastic use in the past 8 weeks</li> <li>Loss of intestinal function (ileus/obstruction)</li> <li>Recent procedures (Enema/NG Tube/Surgical Procedure)</li> </ul>

## Antibiotic Selection



## Notes

- If ongoing therapy with *C. difficile* predisposing antimicrobial regimen, upon completion of 10-14 days of QID dosing continue enteral vancomycin BID until completion of therapy
- Discontinue PPIs, H2 Blockers, and antacids if no ongoing indication
  - Exclusion: GI bleed, *H.pylori* infection, gastric/duodenal ulcer, erosive esophagitis, chronic NSAID/steroid use (>20 mg/day prednisone equivalent)
- Antimicrobial therapy should be narrowed when possible and treatment should be for the shortest duration clinically necessary

ANMC Antimicrobial Stewardship Program Approved May 2017